Key statistics
On Friday, Ascentage Pharma Group International (6855:HKG) closed at 44.10, -9.72% below its 52-week high of 48.85, set on Oct 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 44.50 |
---|---|
High | 45.55 |
Low | 43.00 |
Bid | 44.05 |
Offer | 44.10 |
Previous close | 44.00 |
Average volume | 1.73m |
---|---|
Shares outstanding | 315.16m |
Free float | 210.60m |
P/E (TTM) | -- |
Market cap | 13.90bn HKD |
EPS (TTM) | -1.36 HKD |
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
- ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
- ASH 2024 | Studies of Olverembatinib Selected for Presentations, Including an Oral Report, for the Seventh Consecutive Year
- Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC
- Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation
- ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress
- Ascentage Pharma Announces 2024 Interim Results
- Registrational Phase III Study of Lisaftoclax in Newly-Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome Cleared by China CDE
More ▼